HarachHR, FranssilaKO, WaseniusVM. 1985. Occult papillary carcinoma of the thyroid. A “normal” finding in Finland. A systematic autopsy study. Cancer, 56:531–538.
4.
PelizzoMR, PiottoA, RubelloD, CasaraD, FassinaA, BusnardoB. 1990. High prevalence of occult papillary thyroid carcinoma in a surgical series for benign thyroid disease. Tumori, 76:255–257.
5.
WangC, CrapoLM. 1997. The epidemiology of thyroid disease and implications for screening. Endocrinol Metab Clin North Am, 26:189–218.
6.
YamamotoY, MaedaT, IzumiK, OtsukaH. 1990. Occult papillary carcinoma of the thyroid. A study of 408 autopsy cases. Cancer, 65:1173–1179.
7.
LangW, BorruschH, BauerL. 1988. Occult carcinomas of the thyroid. Evaluation of 1,020 sequential autopsies. Am J Clin Pathol, 90:72–76.
8.
MitselouA, VougiouklakisT, PeschosD, DallasP, AgnantisNJ. 2002. Occult thyroid carcinoma. A study of 160 autopsy cases. The first report for the region of Epirus-Greece. Anticancer Res, 22:427–432.
9.
SampsonRJ, WoolnerLB, BahnRC, KurlandLT. 1974. Occult thyroid carcinoma in Olmsted County, Minnesota: prevalence at autopsy compared with that in Hiroshima and Nagasaki, Japan. Cancer, 34:2072–2076.
10.
SchottenfeldD, GershmanST. 1977. Epidemiology of thyroid cancer—part I. Clin Bull, 7:47–54.
11.
WardLS, MorariEC, LeiteJL, BufaloNE, GuilhenAC, de AraujoPP, TincaniAJ, AssumpcaoLV, MatosPS. 2007. Identifying a risk profile for thyroid cancer. Arq Bras Endocrinol Metabol, 51:713–722.
12.
ChowSM, LawSC, ChanJK, AuSK, YauS, LauWH. 2003. Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. Cancer, 98:31–40.
13.
CheemaY, RepplingerD, ElsonD, ChenH. 2006. Is tumor size the best predictor of outcome for papillary thyroid cancer?. Ann Surg Oncol, 13:1524–1528.
14.
PakdamanMN, RochonL, GologanO, TamiliaM, GarfieldN, HierMP, BlackMJ, PayneRJ. 2008. Incidence and histopathological behavior of papillary microcarcinomas: study of 429 cases. Otolaryngol Head Neck Surg, 139:718–722.
15.
RotiE, RossiR, TrasforiniG, BertelliF, AmbrosioMR, BusuttiL, PearceEN, BravermanLE, Degli UbertiEC. 2006. Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. J Clin Endocrinol Metab, 91:2171–2178.
16.
ItoK, MiyauchiA, KiharaM, HigashiyamaT, KobayashiK, MiyaA. 2014. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid, 24:27–34.
17.
SugitaniI, TodaK, YamadaK, YamamotoN, IkenagaM, FujimotoY. 2010. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg, 34:1222–1231.
18.
CooperDS, DohertyGM, HaugenBR, KloosRT, LeeSL, MandelSJ, MazzaferriEL, McIverB, PaciniF, SchlumbergerM, ShermanSI, StewardDL, TuttleRM. 2009. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 19:1167–1214.
19.
ItoY, TomodaC, UrunoT, TakamuraY, MiyaA, KobayashiK, MatsuzukaF, KumaK, MiyauchiA. 2005. Ultrasonographically and anatomopathologically detectable node metastases in the lateral compartment as indicators of worse relapse-free survival in patients with papillary thyroid carcinoma. World J Surg, 29:917–920.
20.
RohJL, KimJM, ParkCI. 2008. Central cervical nodal metastasis from papillary thyroid microcarcinoma: pattern and factors predictive of nodal metastasis. Ann Surg Oncol, 15:2482–2486.
21.
SoYK, SonYI, HongSD, SeoMY, BaekCH, JeongHS, ChungMK. 2010. Subclinical lymph node metastasis in papillary thyroid microcarcinoma: a study of 551 resections. Surgery, 148:526–531.
22.
WadaN, DuhQY, SuginoK, IwasakiH, KameyamaK, MimuraT, ItoK, TakamiH, TakanashiY. 2003. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg, 237:399–407.
GiordanoD, ValcaviR, ThompsonGB, PedroniC, RennaL, GradoniP, BarbieriV. 2012. Complications of central neck dissection in patients with papillary thyroid carcinoma: results of a study on 1087 patients and review of the literature. Thyroid, 22:911–917.
25.
TufanoRP, BishopJ, WuG. 2012. Reoperative central compartment dissection for patients with recurrent/persistent papillary thyroid cancer: efficacy, safety, and the association of the BRAF mutation. Laryngoscope, 122:1634–1640.
26.
ShenWT, OgawaL, RuanD, SuhI, KebebewE, DuhQY, ClarkOH. 2010. Central neck lymph node dissection for papillary thyroid cancer: comparison of complication and recurrence rates in 295 initial dissections and reoperations. Arch Surg, 145:272–275.
27.
SosaJA, BowmanHM, TielschJM, PoweNR, GordonTA, UdelsmanR. 1998. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg, 228:320–330.
28.
CastroMR, CaraballoPJ, MorrisJC. 2002. Effectiveness of thyroid hormone suppressive therapy in benign solitary thyroid nodules: a meta-analysis. J Clin Endocrinol Metab, 87:4154–4159.
29.
SdanoMT, FalcigliaM, WelgeJA, StewardDL. 2005. Efficacy of thyroid hormone suppression for benign thyroid nodules: meta-analysis of randomized trials. Otolaryngol Head Neck Surg, 133:391–396.
30.
FogelfeldL, WiviottMB, Shore-FreedmanE, BlendM, BekermanC, PinskyS, SchneiderAB. 1989. Recurrence of thyroid nodules after surgical removal in patients irradiated in childhood for benign conditions. N Engl J Med, 320:835–840.
31.
PapiniE, PetrucciL, GuglielmiR, PanunziC, RinaldiR, BacciV, CrescenziA, NardiF, FabbriniR, PacellaCM. 1998. Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules. J Clin Endocrinol Metab, 83:780–783.
32.
JonklaasJ, SarlisNJ, LitofskyD, AinKB, BigosST, BrierleyJD, CooperDS, HaugenBR, LadensonPW, MagnerJ, RobbinsJ, RossDS, SkarulisM, MaxonHR, ShermanSI. 2006. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid, 16:1229–1242.
33.
SawinCT, GellerA, WolfPA, BelangerAJ, BakerE, BacharachP, WilsonPW, BenjaminEJ, D'AgostinoRB. 1994. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med, 331:1249–1252.
34.
UzzanB, CamposJ, CucheratM, NonyP, BoisselJP, PerretGY. 1996. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab, 81:4278–4289.
35.
GrussendorfM, ReinersC, PaschkeR, WegscheiderK. 2011. Reduction of thyroid nodule volume by levothyroxine and iodine alone and in combination: a randomized, placebo-controlled trial. J Clin Endocrinol Metab, 96:2786–2795.
36.
KocM, ErsozHO, AkpinarI, Gogas-YavuzD, DeyneliO, AkalinS. 2002. Effect of low- and high-dose levothyroxine on thyroid nodule volume: a crossover placebo-controlled trial. Clin Endocrinol (Oxf ), 57:621–628.
37.
FioreE, RagoT, ProvenzaleMA, ScutariM, UgoliniC, BasoloF, Di CoscioG, MiccoliP, GrassoL, PincheraA, VittiP. 2010. L-thyroxine-treated patients with nodular goiter have lower serum TSH and lower frequency of papillary thyroid cancer: results of a cross-sectional study on 27 914 patients. Endocr Relat Cancer, 17:231–239.
